Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research... Show more
SOPHiA GENETICS is an AI-native healthcare technology company whose SOPHiA DDM platform analyzes genomic and multimodal data to support cancer and rare-disease care. Its quarterly results are closely watched because they show whether revenue growth is translating into operating leverage and a clearer path to profitability. The company has delivered accelerating growth through 2026, but it remains unprofitable on an IFRS (International Financial Reporting Standards) basis, making the trajectory of its adjusted EBITDA loss and its gross margin central to the investment case. With new products such as liquid biopsy and companion diagnostics ramping and biopharma collaborations expanding, this quarter offered investors a progress check on both the pace of adoption and the quality of the company's cost discipline.
SOPHiA GENETICS reported third quarter 2026 revenue of $24.3 million, an increase of 25% year over year (26% on a constant currency basis) from $19.5 million a year earlier, modestly ahead of consensus. Platform analysis volume reached a record 118,000, up 19% year over year, with North America revenue up 41% and Asia-Pacific up 33%.
Adjusted gross margin came in at 72.8%, and the adjusted EBITDA loss narrowed 31% to $6.1 million. On an IFRS basis, however, the net loss was $20.3 million, essentially flat with $20.0 million a year ago, while the loss per share of ($0.24) improved from ($0.30) but came in wider than the roughly ($0.13) consensus estimate, partly reflecting share-based compensation, litigation, and warrant fair-value adjustments.
Management guided full-year 2026 revenue to the upper end of its $94–$96 million range and reaffirmed the adjusted EBITDA loss outlook of $29–$32 million, while reiterating a goal of positive adjusted EBITDA in the second half of 2027.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those monitoring earnings-driven movers like SOPH, it offers a structured way to identify related opportunities across the healthcare technology landscape.
Heading into the report, sentiment had already turned more constructive, with shares trading well above their 200-day moving average. The third quarter showed a fundamental improvement that the headline EPS (earnings per share) miss obscures: revenue beat estimates, net dollar retention improved to 118%, churn remained below 1%, and liquid biopsy and biopharma momentum continued to build. Still, investors are weighing a familiar tension. Operating losses were flat in dollar terms, and per-share improvement partly reflects a larger share count following equity raises. The result is a growth story that is scaling, but one where the benefits have not yet fully reached the bottom line shareholders own.
The most important near-term signal is whether the company can sustain its revenue trajectory while continuing to narrow adjusted EBITDA losses. Management expects to convert a substantial portion of incremental revenue to the bottom line, and the reaffirmed target of positive adjusted EBITDA in the second half of 2027 makes profitability the central test for investors.
Several catalysts bear watching. Liquid biopsy adoption is ramping quickly, with volumes more than doubling year over year, and recent signings are expected to contribute meaningfully in the fourth quarter and into 2027. New biopharma collaborations, including companion diagnostic programs, could add high-value revenue, though their timing depends on implementation and ramp schedules.
On the risk side, investors should monitor the pace of U.S. growth, which decelerated from elevated levels, as well as foreign exchange effects and recurring items such as share-based compensation, litigation expense, and warrant fair-value adjustments that continue to weigh on reported results. The balance between reinvestment for growth and disciplined cost control will shape how quickly the company approaches breakeven.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry ServicestotheHealthIndustry